Overview of Glaukos iStent-W, Update on Vabysmo & Screening of Diabetes and Safety of antiVEGF in Pregnancy
Date: 8/08/2023 (AEST)
Venue: St Andrew's Hospital, Rockville , QLD, 4350
Provider: Dr Andrew McAllister
Contact: Joyce Law, [E] eyes@toowoombaretina.com.au, [P] 0745800857
Learning Objectives
- Revise on iStent clinical application
- Updates on long term clinical results for pressure control of patients with iStent implanted
- Calculate Ocular Surface Disease Index (OSDI) score for dry eye patients
- Optometrists' perspective of care improving patient's Quality of Life post iStent implantation
- Overview of real world and safety profile of iStent implantation procedure (including Endothelial Cell Loss)
- Introduction on the new anti-VEGF Vabysmo (Faricimab) treatment for AMD and DMO patients.
- Understanding of Medicare requirements/PBS indications for approval of Anti-VEGF treatments
- Overview of the Anti-VEGF market
- Updates on future treatments/ latest Anti-VEGF to be approved by the TGA
- Ophthalmologist perspective: early experience of Vabysmo
- Safety of antiVEGF with pregnancy
- Update of screening for diabetes in pregnancy
Max CPD hours awarded: 2
Session Information
| Name |
|---|
| Overview of Glaukos iStent-W, Update on Vabysmo & Screening of Diabetes and Safety of antiVEGF in Pregnancy |
| Clinical? |
| Yes |
| Interactive? |
| Yes |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 1.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 2 |